Susquehanna International Group’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Susquehanna International Group’s Portfolio IDXG Stock Details IDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,486	Closed	-$7K	–	11370
2019 Q4	$7K	Sell	1,486 -1,434	-49%	-$9.28K	﹤0.01%	9574
2019 Q3	$23K	Buy	+2,920	New	+$22.8K	﹤0.01%	9937
2019 Q2	–	Sell	-2,575	Closed	-$21K	–	11183
2019 Q1	$21K	Buy	+2,575	New	+$24.2K	﹤0.01%	8593
2017 Q3	–	Sell	-71,808	Closed	-$646K	–	10018
2017 Q2	$646K	Buy	+71,808	New	+$1.41M	﹤0.01%	6152
2017 Q1	–	Sell	-1,448	Closed	-$64K	–	10490
2016 Q4	$64K	Buy	+1,448	New	+$46.2K	﹤0.01%	9227

Other funds holding IDXG

PCM

Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Susquehanna International Group's IDXG Position: Q1 2020 in Review

Susquehanna International Group sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2020, closing a stake of 1,486 shares — an estimated $7K sold.

Susquehanna International Group first reported a position in IDXG in Q4 2016 and held it in 5 quarters. The position peaked at $646K in Q2 2017. 15 funds tracked by Wall St. Rank hold IDXG as of Q1 2020.

Susquehanna International Group reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
Susquehanna International Group sold 1,486 Interpace Biosciences, Inc. Common Stock shares in Q1 2020, an estimated $7K.
Susquehanna International Group first reported a position in Interpace Biosciences, Inc. Common Stock in Q4 2016 and held it in 5 quarters.
Susquehanna International Group's Interpace Biosciences, Inc. Common Stock position peaked at $646K in Q2 2017.
15 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2020.

Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.